La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Neuren Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Neuren Pharmaceuticals ha un patrimonio netto totale di A$205.2M e un debito totale di A$0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente A$248.0M e A$42.8M. L'EBIT di Neuren Pharmaceuticals è A$199.2M rendendo il suo rapporto di copertura degli interessi -35. Ha liquidità e investimenti a breve termine pari a A$228.5M.

Informazioni chiave

Rapporto debito/patrimonio netto

AU$0

Debito

Indice di copertura degli interessi	-14.3x
Contanti	AU$213.17m
Patrimonio netto	AU$219.15m
Totale passività	AU$9.00m
Totale attività	AU$228.15m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( A$247.2M ) di NEU superano le sue passività a breve termine ( A$42.8M ).

Passività a lungo termine: Le attività a breve termine di NEU ( A$228.0M ) superano le sue passività a lungo termine ( A$29.0K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: NEU è esente da debiti.

Riduzione del debito: NEU non ha avuto debiti negli ultimi 5 anni.

Copertura del debito: NEU non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: NEU non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.

Neuren Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

First half 2024 earnings released: EPS: AU$0.063 (vs AU$0.38 in 1H 2023)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 16%

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Investor sentiment improves as stock rises 38%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

New 90-day low: AU$1.26

Full year 2020 earnings released: AU$0.086 loss per share (vs AU$0.11 loss in FY 2019)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.40

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

New 90-day high: AU$1.30

New 90-day low: AU$1.06

New 90-day low: AU$1.10

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane